Digistain: A Novel, Rapid, and Cost-effective Prognostic Marker for Guiding Adjuvant Therapy in ER+, HER2-Breast Cancer

被引：0
|
作者：
Amrania, Hemmel [1 ]
机构：
[1] Imperial Coll London, Harrow, Middx, England
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1387998
引用
收藏
页码：S321 / S321
页数：1
相关论文
共 50 条
  • [21] Response of persistent metastatic ER+/Her2-breast cancer treated with fulvestrant plus enzalutamide
    Richer, Jennifer
    Spoelstra, Nicole
    Winchester, Alyse
    Wulfkuhlue, Julia
    Gallagher, Rosa
    Sams, Sharon
    Vidal, Gregory
    Kabos, Peter
    Diamond, Jennifer
    Shagisultanova, Elena
    Afghahi, Anosheh
    Mayordomo, Jose
    McSpadded, Tessa
    Crawford, Gloria
    Borges, Virginia
    Gao, Dexiang
    Petricoin, Emanuel
    Elias, Anthony
    CANCER RESEARCH, 2022, 82 (04)
  • [22] The EndoPredict score identifies late distant metastases in ER+/HER2-breast cancer patients
    Dubsky, P.
    Brase, J. C.
    Fisch, K.
    Jakesz, R.
    Singer, C. F.
    Greil, R.
    Dietze, O.
    Weber, K. E.
    Petry, C.
    Kronenwett, R.
    Rudas, M.
    Knauer, M.
    Gnant, M.
    Filipits, M.
    CANCER RESEARCH, 2012, 72
  • [23] Hormone receptor alterations and treatment responses after neoadjuvant therapy in patients with ER+/HER2-breast cancer.
    Maeda, Shigeto
    Tohyama, Hiroaki
    Tokai, Yukiko
    Nakashima, Kazuaki
    Kamohara, Yukio
    Nagata, Yasuhiro
    Ito, Masahiro
    Fujioka, Hikaru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2-Breast Cancer
    Oshi, Masanori
    Takahashi, Hideo
    Tokumaru, Yoshihisa
    Yan, Li
    Rashid, Omar M.
    Nagahashi, Masayuki
    Matsuyama, Ryusei
    Endo, Itaru
    Takabe, Kazuaki
    CELLS, 2020, 9 (07) : 1 - 19
  • [25] Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER, part 1)
    Spring, Laura M.
    Scarpetti, Lauren
    Niemierko, Andrzej
    Isakoff, Steven J.
    Moy, Beverly
    Wander, Seth A.
    Smith, Elisabeth
    Abraham, Elizabeth
    Shin, Jennifer
    Patel, Jaymin M.
    Comander, Amy
    Mulvey, Therese
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [26] Outcome without any adjuvant systemic treatment in stage I ER+/HER2-breast cancer patients included in the MINDACT trial
    Cardozo, J. M. N. Lopes
    Byng, D.
    Drukker, C. A.
    Schmidt, M. K.
    Binuya, M. A.
    Veer, L. J. van 't
    Cardoso, F.
    Piccart, M.
    Smorenburg, C. H.
    Poncet, C.
    Rutgers, E. J. T.
    ANNALS OF ONCOLOGY, 2022, 33 (03) : 310 - 320
  • [27] ASO Author Reflections: The Changing Role of Gene Expression Profiling in ER+/HER2-Breast Cancer
    van Steenhoven, Julia E. C.
    van Dalen, T.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (Suppl 3) : S800 - S801
  • [28] Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2-Breast Cancer
    Song, Ran
    Lee, Dong-Eun
    Lee, Eun-Gyeong
    Lee, Seeyoun
    Kang, Han-Sung
    Han, Jai Hong
    Lee, Keun Seok
    Sim, Sung Hoon
    Chae, Heejung
    Kwon, Youngmee
    Woo, Jaeyeon
    Jung, So-Youn
    CANCERS, 2023, 15 (18)
  • [29] Molecular stratification of ER+/HER2-breast cancer cell lines to predict sensitivity to targeted agents
    Bathurst, L.
    Liao, L.
    Crozier, C.
    Lyttle, N.
    Marcellus, R.
    Bayani, J.
    Al-Awar, R.
    Bartlett, J.
    Spears, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [30] Role of androgen receptor expression in early stage ER+/PgR-/HER2-breast cancer
    Tagliaferri, Barbara
    Quaquarini, Erica
    Palumbo, Raffaella
    Balletti, Emanuela
    Presti, Daniele
    Malovini, Alberto
    Agozzino, Manuela
    Teragni, Cristina Maria
    Terzoni, Andrea
    Bernardo, Antonio
    Villani, Laura
    Sottotetti, Federico
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
12345